We addressed in this study (i) the RSK activity in BRAFV600E/K inhibitor resistant melanoma cells, (ii) the effect of RSK inhibition on the viability of BRAFV600E/K and MAPK inhibitor resistant cells and (iii) the impact of the RSK target YB-1 on the sensitivity towards BRAF inhibition. This evidence concerns the gene BRAF and melanoma.